Metraipolis › archive › dc_994d33ce7567

PRIME-Teen-Treatment Persistence and Outcomes Associated with CGRP Monoclonal Antibodies Compared with Conventional Oral Preventives in Adolescents with… — Europe PMC PMID:41827393

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41827393
DOI
10.3390/jcm15051976
License (as archived)
solo-consultazione
Archived
2026-11-05T03:14:43.796Z
SHA-256 of the archived text
e6a7acbac5f9841552243eeb742096c8b44f92227eacdce8cc9b82a981df0b33
Stable URL of this page
https://metraipolis.com/documento/dc_994d33ce7567

How to cite

PRIME-Teen-Treatment Persistence and Outcomes Associated with CGRP Monoclonal Antibodies Compared with Conventional Oral Preventives in Adolescents with… — Europe PMC PMID:41827393 — Europe PMC (en), https://europepmc.org/article/MED/41827393 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_994d33ce7567 (Metraipolis archive dc_994d33ce7567, sha256 e6a7acbac5f9841552243eeb742096c8b44f92227eacdce8cc9b82a981df0b33)
BibTeX
@misc{dc994d33ce7567,
  title = {PRIME-Teen-Treatment Persistence and Outcomes Associated with CGRP Monoclonal Antibodies Compared with Conventional Oral Preventives in Adolescents with… — Europe PMC PMID:41827393},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41827393},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_994d33ce7567; sha256 e6a7acbac5f9841552243eeb742096c8b44f92227eacdce8cc9b82a981df0b33},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41827393. Agents can read the archived copy with the MCP tool read_document.